Ingredion announces strategic investments expanding into high-value pharmaceutical ingredients

Ingredion logo

WESTCHESTER, March 24, 2023 - Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, today announced that it has completed two strategic investments in India to expand into high-value pharmaceutical applications.

During the third quarter of 2022, the Company acquired Amishi Drugs & Chemicals (AD&C), headquartered in Ahmedabad, India, which manufactures superdisintegrants, lubricants, and viscosifiers complementing its portfolio of starch, mannitol, and dextrose product offerings.

In the fourth quarter of 2022, the Company secured a majority position in Mannitab Pharma Specialities, based out of Malegaon, India. Started by M.B. Sugars, a leading supplier of specialty sugars to the pharmaceutical industry in India, Mannitab produces spray-dried mannitol for direct compression. The Company’s investment will further expand Mannitab’s manufacturing capacity and support global exports.

“These investments are part of our strategy to expand our specialty pharmaceutical product portfolio to better serve our customers and diversify into high-value nonfood adjacencies,” said Jim Zallie, Ingredion’s President and CEO.

As a result of these strategic investments, the Company’s portfolio of functional excipients now includes binders, fillers, superdisintegrants, lubricants, gelatine replacers for softgels, viscosifiers, encapsulation materials, and parenteral grade dextrose. The Company manufactures these highly functional materials under stringent pharma Good Manufacturing Practices (GMPs) and supports its customers with regulatory expertise and collaborative technical support. 

“Ingredion looks forward to partnering with pharma and nutraceutical formulators and helping them meet regulatory challenges, progress drug development, and identify emerging trends,” added Rana Kayal, Global Director for Pharma & Nutraceuticals.